Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34(+) Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

SIMPLE SUMMARY: Epigenetic drugs, such as azacitidine (AZA), hold promise in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), however, the mechanisms predicting the patients’ response to AZA is not completely understood. Quiescence of hematopoietic CD34(+) progenito...

Descripción completa

Detalles Bibliográficos
Autores principales: Koralkova, Pavla, Belickova, Monika, Kundrat, David, Dostalova Merkerova, Michaela, Krejcik, Zdenek, Szikszai, Katarina, Kaisrlikova, Monika, Vesela, Jitka, Vyhlidalova, Pavla, Stetka, Jan, Hlavackova, Alzbeta, Suttnar, Jiri, Flodr, Patrik, Stritesky, Jan, Jonasova, Anna, Cermak, Jaroslav, Divoky, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125503/
https://www.ncbi.nlm.nih.gov/pubmed/33946220
http://dx.doi.org/10.3390/cancers13092161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125503/
https://www.ncbi.nlm.nih.gov/pubmed/33946220
http://dx.doi.org/10.3390/cancers13092161

Ejemplares similares